Ecobiotherapy rich in firmicutes decreases susceptibility to colitis in a humanized gnotobiotic mouse model

Inflammatory Bowel Diseases

Volumn 21, Issue 8, 2015, Pages 1883-1893

  Natividad, Jane M ^a   Pinto Sanchez, Maria I ^a   Galipeau, Heather J ^a   Jury, Jennifer ^a   Jordana, Manel ^b   Reinisch, Walter ^a   Collins, Stephen M ^a   Bercik, Premsyl ^a   Surette, Michael G ^a   Allen Vercoe, Emma ^c   Verdu, Elena F ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

Author keywords

Firmicutes; Microbiota; TH17; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ALBUMIN; BACTERIUM LYSATE; DEXTRAN SULFATE; INTERLEUKIN 17; METHYLPREDNISOLONE; MYELOPEROXIDASE; PREDNISONE; RNA 16S; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL THERAPY; COLITIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; ECOBIOTHERAPY; ECOSYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL COLITIS; FIRMICUTES; FLOW CYTOMETRY; GNOTOBIOTICS; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INTESTINE FLORA; INTESTINE INJURY; LAMINA PROPRIA; LYMPHOCYTE DIFFERENTIATION; MICROFLORA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; RNA SEQUENCE; T LYMPHOCYTE; TH17 CELL; ULCERATIVE COLITIS; ANIMAL; C57BL MOUSE; CELL DIFFERENTIATION; DISEASE MODEL; FECES; FEMALE; GERMFREE ANIMAL; IMMUNOLOGY; INTESTINE MUCOSA; MALE; MICROBIOLOGY; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; COLITIS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; FECES; FEMALE; FIRMICUTES; FLOW CYTOMETRY; GERM-FREE LIFE; HUMANS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; MICROBIOTA;

EID: 84946920888     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000422     Document Type: Article

References (44)

1. El Aidy S, van Baarlen P, Derrien M, et al. Temporal and spatial interplay of microbiota and intestinal mucosa drive establishment of immune homeostasis in conventionalized mice. Mucosal Immunol. 2012;5:567-579.
2. Natividad JM, Hayes CL, Motta JP, et al. Differential induction of antimicrobial REGIII by the intestinal microbiota and Bifidobacterium breve NCC2950. Appl Environ Microbiol. 2013;79:7745-7754.
3. Smith K, McCoy KD, Macpherson AJ. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Semin Immunol. 2007;19:59-69.
4. Hooper LV, Wong MH, Thelin A, et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science. 2001;291:881-884.
5. Devkota S, Wang Y, Musch MW, et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature. 2012;487:104-108.
6. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139:485-498.
7. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008;453:620-625.
8. Chow J, Tang H, Mazmanian SK. Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr Opin Immunol. 2011;23:473-480.
9. Rabizadeh S, Rhee KJ, Wu S, et al. Enterotoxigenic bacteroides fragilis: a potential instigator of colitis. Inflamm Bowel Dis. 2007;13:1475-1483.
10. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55-60.
11. Frank D, St Amand A, Feldman R, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104:13780-13785.
12. Sartor RB, Mazmanian SK. Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol. 2012;1:15-21.
13. Kassam Z, Hundal R, Marshall J, et al. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch Intern Med. 2012;172:191-193.
14. Moayyedi P, Surette M, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized, controlled trial. Gastroenterology. [published online ahead of print April 6, 2015]. 10.1053/j.gastro.2015.04.001.
15. Petrof E, Gloor G, Vanner S, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: "RePOOPulating" the gut. Microbiome. 2013;1:3.
16. Slack E, Hapfelmeier S, Stecher B, et al. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science. 2009;325:617-620.
17. Dewhirst FE, Chien C-C, Paster BJ, et al. Phylogeny of the defined murine microbiota: altered Schaedler flora. Appl Environ Microbiol. 1999;65:3287-3292.
18. Natividad JM, Petit V, Huang X, et al. Commensal and probiotic bacteria influence intestinal barrier function and susceptibility to colitis in Nod1-/-; Nod2-/- mice. Inflamm Bowel Dis. 2012;18:1434-1446.
19. Whelan FJ, Verschoor CP, Stearns JC, et al. The loss of topography in the microbial communities of the upper respiratory tract in the elderly. Ann Am Thorac Soc. 2014;11:513-521.
20. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7:335-336.
21. Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7:562-578.
22. Geuking MB, Cahenzli J, Lawson MA, et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity. 2011;34:794-806.
23. Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511-515.
24. Turnbaugh PJ, Quince C, Faith JJ, et al. Organismal, genetic, and transcriptional variation in the deeply sequenced gut microbiomes of identical twins. Proc Natl Acad Sci U S A. 2010;107:7503-7508.
25. Yosef N, Shalek A, Gaublomme J, et al. Dynamic regulatory network controlling TH17 cell differentiation. Nature. 2013;496:461-468.
26. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235-238.
27. Bettelli E, Oukka M, Kuchroo V. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8:345-350.
28. Yang X, Chang S, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205:1063-1075.
29. Deenick E, Tangye S. Autoimmunity: IL-21: a new player in Th17-cell differentiation. Immunol Cell Biol. 2007;85:503-505.
30. Ivanov I, Frutos R, Manel N, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 2008;4:337-349.
31. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59-65.
32. Angelberger S, Reinisch W, Makristathis A, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 2013;108:1620-1630.
33. Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500:232-236.
34. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105:16731-16736.
35. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635-1638.
36. Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2012;9:88-96.
37. Dong Z, Du L, Xu X, et al. Aberrant expression of circulating Th17, Th1 and Tc1 cells in patients with active and inactive ulcerative colitis. Int J Mol Med. 2013;31:989-997.
38. Olsen T, Rismo R, Cui G, et al. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine. 2011;56:633-640.
39. Geddes K, Rubino SJ, Magalhaes JG, et al. Identification of an innate T helper type 17 response to intestinal bacterial pathogens. Nat Med. 2011;17:837-844.
40. Marwaha AK, Leung NJ, McMurchy AN, et al. TH17 cells in autoimmunity and Immunodeficiency: protective or pathogenic? Front Immunol. 2012;3:129.
41. Lee Y, Awasthi A, Yosef N, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol. 2012;13:991-999.
42. Vaarala O, Atkinson M, Neu J. The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes. 2008;57:2555-2562.
43. Weaver CT, Elson CO, Fouser LA, et al. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol. 2013;8:477-512.
44. Ogawa A, Andoh A, Araki Y, et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol. 2004;110:55-62.